Literature DB >> 16762622

Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome.

Isis Dove-Edwin1, Andrea E de Jong, Joanna Adams, David Mesher, Lara Lipton, Peter Sasieni, Hans F A Vasen, Huw J W Thomas.   

Abstract

BACKGROUND & AIMS: Lynch syndrome is an autosomal dominant predisposition to colorectal cancer caused by mutations in DNA mismatch repair genes; colorectal cancer risk is high. Few studies have addressed colorectal cancer risk in individuals from dominant families without mismatch repair deficiency. We sought to establish whether these individuals are also at increased risk by examining the incidence of advanced neoplasia during surveillance.
METHODS: In this prospective cohort study, BAT26 testing of tumors was carried out at 2 tertiary centers on 125 individuals from 97 families (with a dominant colorectal cancer history) to classify families as Lynch syndrome (microsatellite unstable) or non-Lynch syndrome (microsatellite stable). Colonoscopy results in 288 at-risk family members were compared.
RESULTS: Twenty-nine families were classified as Lynch syndrome and 68 as non-Lynch syndrome. Seven hundred seventy-six colonoscopies were undertaken. High-risk adenomas occurred in 7 of 91 (7.7%) Lynch syndrome individuals and 15 of 197 (7.6%) non-Lynch syndrome individuals, adjusted relative risk 1.15 (95% CI: 0.6-2.3). Cancer was observed only in Lynch syndrome individuals (4/91; 4.4%), Fisher exact test, P = .010. Multiple adenomas were only seen in non-Lynch syndrome individuals (13/197; 6.6%), Fisher exact text, P = .06.
CONCLUSIONS: Individuals with an autosomal dominant family history of colorectal cancer with and without evidence of Lynch syndrome are at equal risk of high-risk adenomas during surveillance, but colorectal cancer was only seen in Lynch syndrome. Therefore non-Lynch syndrome individuals do require colonoscopic surveillance, but the interval could be lengthened because risk of (interval) cancer is low. Lynch syndrome individuals require short surveillance intervals as is the recommended practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762622     DOI: 10.1053/j.gastro.2006.03.018

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

Review 2.  Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome.

Authors:  Noralane M Lindor
Journal:  Surg Oncol Clin N Am       Date:  2009-10       Impact factor: 3.495

Review 3.  Clinical management of hereditary colorectal cancer syndromes.

Authors:  Hans F A Vasen; Ian Tomlinson; Antoni Castells
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-13       Impact factor: 46.802

4.  Speed kills.

Authors:  C Richard Boland
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-30       Impact factor: 11.382

5.  Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer.

Authors:  Luis Bujanda; Cristina Sarasqueta; Leire Zubiaurre; Angel Cosme; Carmen Muñoz; Araceli Sánchez; Cristina Martín; Llucia Tito; Virginia Piñol; Antoni Castells; Xavier Llor; Rosa M Xicola; Elisenda Pons; Juan Clofent; María L de Castro; Jaime Cuquerella; Enrique Medina; Ana Gutierrez; Juan I Arenas; Rodrigo Jover
Journal:  Gut       Date:  2007-03-30       Impact factor: 23.059

6.  How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

Authors:  Janneke A Wilschut; Ewout W Steyerberg; Monique E van Leerdam; Iris Lansdorp-Vogelaar; J Dik F Habbema; Marjolein van Ballegooijen
Journal:  Cancer       Date:  2011-03-08       Impact factor: 6.860

7.  Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study.

Authors:  Gabriel Rahmi; Thierry Lecomte; David Malka; Thibault Maniere; Marc Le Rhun; Rosine Guimbaud; Marie-Georges Lapalus; Anne Le Sidaner; Driffa Moussata; Olivier Caron; Jean-Pierre Barbieux; Marianne Gaudric; Emmanuel Coron; Karl Barange; Thierry Ponchon; Denis Sautereau; Elia Samaha; Jean-Christophe Saurin; Stanislas Chaussade; Pierre Laurent-Puig; Gilles Chatellier; Christophe Cellier
Journal:  Am J Gastroenterol       Date:  2015-01-20       Impact factor: 10.864

8.  Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2.

Authors:  Annelie Liljegren; Gail Barker; Faye Elliott; Lucio Bertario; Marie Luise Bisgaard; Diana Eccles; Gareth Evans; Finlay Macrae; Eamonn Maher; Annika Lindblom; Samuel Rotstein; Bo Nilsson; Jukka-Pekka Mecklin; Gabriela Möslein; Jeremy Jass; Riccardo Fodde; John Mathers; John Burn; D Timothy Bishop
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

9.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

Review 10.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).

Authors:  H F A Vasen; G Möslein; A Alonso; I Bernstein; L Bertario; I Blanco; J Burn; G Capella; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; J-P Mecklin; P Møller; F Nagengast; Y Parc; L Renkonen-Sinisalo; J R Sampson; A Stormorken; J Wijnen
Journal:  J Med Genet       Date:  2007-02-27       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.